CRVS - Company ID 0001626971
The table below shows Corvus Pharmaceuticals, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.58M | $8.74M | $12.62M | $13.16M | $16.45M | $5.15M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $37.00K | $75.00K | $26.00K | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $58.21M |
| $54.41M |
| $27.96M |
| $43.66M |
| $45.34M |
| $79.34M |
| Property, plant & equipment | $220.00K | $151.00K | $236.00K | $353.00K | $906.00K | $1.46M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $71.12M | $68.91M | $45.55M | $68.24M | $85.53M | $83.65M |
| Accounts payable | $2.49M | $2.58M | $1.52M | $1.98M | $3.47M | $2.45M |
| Total current liabilities | $9.38M | $35.40M | $6.87M | $10.75M | $12.15M | $10.22M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $9.91M | $36.34M | $6.87M | $12.13M | $13.38M | $12.54M |
| Retained earnings | -$412.29M | -$397.01M | -$334.72M | -$307.69M | -$223.14M | -$217.15M |
| Total equity | $61.20M | $32.57M | $38.68M | $56.12M | $72.15M | $71.11M |